AstraZeneca and Daiichi Sankyo have secured US Food and Drug Administration (FDA) approval for a new form of chemotherapy to treat advanced breast cancer. The drug, called Datroway or Dato-DXd, is now available for certain patients with this aggressive type of cancer.
Datroway was previously approved in Japan last month, marking its first regulatory approval globally. In the US, the list price of the drug is around $4,900 per 100 milligram vial. The recommended dose for treatment will be 6 milligrams per kilogram of patient weight, administered every three weeks.
Source: https://www.statnews.com/2025/01/19/astrazeneca-daiichi-sankyo-breast-cancer-datroway-dato-dxd